Keith Moore
Sanotize Research and Development corp. · SaNOtize R&D Corp · kmoore@sanotize.com
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Keith Moore as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:04 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06264141 · Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute RhinosinusitisSanotize Research and Development corp. · completed · Recurrent Acute Rhinosinusitis · study director
- Ph1NCT06120816 · Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal CandidiasisSanotize Research and Development corp. · completed · Candidiasis, Oral · study director
- Ph2NCT05877313 · Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)Sanotize Research and Development corp. · completed · Verruca Plantaris · study director
- Ph3NCT05599919 · Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19Sanotize Research and Development corp. · completed · SARS-CoV-2 Infection · study director
- Ph3NCT05109611 · Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 InfectionSanotize Research and Development corp. · terminated · SARS-CoV-2 Infection · study director
- Ph3NCT00655291 · Efficacy of XP20B Following Bunionectomy SurgeryXanodyne Pharmaceuticals · completed · Acute Pain · unknown
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:04 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:04 UTC. The ranking covers the 200 most relevant of 349 PubMed records, and a shared surname and initials can bring in a namesake. All 349 on PubMed
- 2,326 citationsRCR 81.5
- 1,541 citationsRCR 71.0
- Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med · 20071,430 citationsRCR 43.4
- Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.J Clin Oncol · 20091,281 citationsRCR 31.5
- Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial.J Clin Oncol · 20201,110 citationsRCR 51.8
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.N Engl J Med · 2019733 citationsRCR 27.1
- Effects of exercise training on older patients with major depression.Arch Intern Med · 1999673 citationsRCR 22.2
- Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months.Psychosom Med · 2000529 citationsRCR 16.4
- Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.J Clin Oncol · 2023441 citationsRCR 39.9
- 436 citationsRCR 41.6